Details

Autor(en) / Beteiligte

• Sultana, Sharmim
• Viet, Thanh Doan
• Amin, Tasmiha
• Kazi, Esha
• Micolucci, Luigina
• Mollah, Abul Kalam Mohammad Moniruzzaman
• Akhtar, Most Mauluda
• Islam, Md Soriful

Titel

Exploring Inflammasome Complex as a Therapeutic Approach in Inflammatory Diseases

Ist Teil von

• Future pharmacology, 2023-11, Vol.3 (4), p.789-818

Ort / Verlag

MDPI AG

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Inflammasomes, a group of multiprotein complexes, are essential in regulating inflammation and immune responses. Several inflammasomes, including nucleotide-binding domain leucine-rich repeat-containing protein 1 (NLRP1), NLRP3, NLRP6, NLRP7, NLRP12, interferon-inducible protein 16 (IFI16), NOD-like receptor family CARD domain-containing protein 4 (NLRC4), absent in melanoma 2 (AIM2), and pyrin, have been studied in various inflammatory diseases. Activating inflammasomes leads to the processing and production of proinflammatory cytokines, such as interleukin (IL)-1β and IL-18. The NLRP3 inflammasome is the most extensively studied and well characterized. Consequently, targeting inflammasomes (particularly NLRP3) with several compounds, including small molecule inhibitors and natural compounds, has been studied as a potential therapeutic strategy. This review provides a comprehensive overview of different inflammasomes and their roles in six inflammatory diseases, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, atherosclerosis, type 2 diabetes, and obesity. We also discussed different strategies that target inflammasomes to develop effective therapeutics.